Trial reportMenopause (New York, N.Y.)2011
Escitalopram treatment of menopausal hot flashes.
Trial report in Menopause (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05346445 (Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials.Iranian journal of medical sciences · 2022Pooled it
- SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.Journal of general internal medicine · 2014Pooled it
- Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.Archives of gynecology and obstetrics · 2022Trial
- Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.Annals of surgical oncology · 2023Review
- Management of Potential Long-Term Toxicities in Breast Cancer Patients.Current breast cancer reports · 2016Article
- A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.SpringerPlus · 2015Article
- Temporal sequencing of brain activations during naturally occurring thermoregulatory events.Cerebral cortex (New York, N.Y. : 1991) · 2014Article
- Menopausal hot flashes: mechanisms, endocrinology, treatment.The Journal of steroid biochemistry and molecular biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThe aim of this study was to determine the effects of 10 and 20 mg/day of escitalopram on objectively recorded hot flashes and on the rectal temperature threshold for sweating.
methodsTwo studies were performed: 16 women received 10 mg/day and 26 women received 20 mg/day escitalopram for 8 weeks. They were randomly assigned in equal numbers to receive active drug or placebo in a double-blind fashion. Hot flash frequency was measured with an ambulatory recorder during the first 3 weeks and during the 8th week of the study. Rectal temperature threshold for sweating was measured during the 1st and 8th weeks of the study using published methods.
resultsIn the first study, there were no significant effects whatsoever for any measure. In the second study, the escitalopram group showed an average decline in hot flash frequency of 14.4%, whereas the placebo group showed an average increase of 6.7% (P < 0.05). However, there were no significant effects across time for either group. There were no significant effects whatsoever for rectal temperature sweating thresholds.
conclusionsEscitalopram at 10 or 20 mg/day is not effective in the treatment of menopausal hot flashes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.